To print this article, all you need is to be registered or login on Mondaq.com.
On October 25, 2022, JSR Life Sciences and Blau Farmaceutica
announced that Similis Bio, JSR Life Sciences’s business unit
focused on biosimilar development, has signed its first development
and license agreement with Blau Farmaceutica, a Brazilian
pharmaceutical company. According to the press release, the agreement contemplates a
multi-product and multi-year deal to develop products and license
intellectual property for four assets targeting indications in
oncology, inflammation and blood disorders.
Under the agreement, Simils Bio will provide full processes and
associated intellectual property for technology transfer to Blau,
which will utilize the intellectual property for GMP manufacturing
and clinical development, and seek regulatory approval. Blau has
exclusive worldwide rights and intends to market independently in
the U.S., and to partner with local organizations in other regions.
The agreement is structured with upfront payments and long-term
royalties upon commercial approval for sale, and the parties expect
the total value of the contract to exceed $100 million. The parties
did not disclose additional financial terms.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Food, Drugs, Healthcare, Life Sciences from United States